|
Aug 5
|
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
|
|
Aug 1
|
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
|
|
Jul 31
|
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
|
|
Jul 31
|
Investors in Arvinas (NASDAQ:ARVN) have unfortunately lost 86% over the last three years
|
|
Jul 31
|
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
|
|
Jul 30
|
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jul 30
|
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
|
|
Jul 24
|
Arvinas, Inc. (ARVN): A Bull Case Theory
|
|
Jul 22
|
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
|
|
Jul 18
|
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
|
|
Jul 17
|
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
|
|
Jul 16
|
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
|
|
Jul 15
|
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment
|
|
Jul 14
|
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
|
|
Jun 16
|
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
|
|
Jun 13
|
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
|
|
Jun 5
|
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
|
|
May 31
|
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
|
|
May 30
|
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
|
|
May 30
|
Arvinas to Present at Jefferies Global Healthcare Conference
|